Allogene Therapeutics (ALLO) Enterprise Value (2018 - 2026)
Allogene Therapeutics (ALLO) reported Enterprise Value of -$261.6 million for Q1 2026, up 6.57% on a YoY basis from -$245.5 million in Q1 2025, and down 4.56% sequentially from -$250.2 million in Q4 2025.
Allogene Therapeutics (ALLO) Enterprise Value (2018 - 2026) Analysis & Trends
Allogene Therapeutics (ALLO) has 9 years of Enterprise Value data on file, last reported at -$261.6 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 6.57% year-over-year to -$261.6 million; the trailing twelve-month figure through Mar 2026 stood at -$261.6 million (up 6.57% YoY), and the FY2025 full-year result was -$250.2 million, up 14.45% from the prior year.
- Enterprise Value eased to -$261.6 million in Q1 2026, from -$250.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$250.2 million in Q4 2025 to a low of -$552.2 million in Q3 2022.
- A 5-year average of -$384.7 million and a median of -$435.5 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value dropped 28.95% in 2022 and soared 38.93% in 2024, its largest moves.
- Tracing ALLO's Enterprise Value over 5 years: stood at -$467.2 million in 2022, then increased by 4.94% to -$444.1 million in 2023, then jumped by 34.14% to -$292.5 million in 2024, then rose by 14.45% to -$250.2 million in 2025, then decreased by 4.56% to -$261.6 million in 2026.
- Business Quant data shows ALLO's Enterprise Value at -$261.6 million in Q1 2026, -$250.2 million in Q4 2025, and -$252.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | -261.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -261.63 Mn |
| Dec 31, 2025 | -250.21 Mn |
| Sep 30, 2025 | -252.19 Mn |
| Jun 30, 2025 | -273.12 Mn |
| Mar 31, 2025 | -280.04 Mn |
| Dec 31, 2024 | -292.48 Mn |
| Sep 30, 2024 | -284.30 Mn |
| Jun 30, 2024 | -435.50 Mn |
| Mar 31, 2024 | -378.84 Mn |
| Dec 31, 2023 | -444.08 Mn |
| Sep 30, 2023 | -465.51 Mn |
| Jun 30, 2023 | -491.96 Mn |
| Mar 31, 2023 | -471.22 Mn |
| Dec 31, 2022 | -467.18 Mn |
| Sep 30, 2022 | -552.23 Mn |
| Jun 30, 2022 | -490.49 Mn |
| Mar 31, 2022 | -449.05 Mn |
| Dec 31, 2021 | -399.86 Mn |
| Sep 30, 2021 | -428.27 Mn |
| Jun 30, 2021 | -587.71 Mn |